

Scancell Holdings PLC

08:42 03 Feb 2020

Morning Report: Scancell receives US approval for its SCIB1 skin cancer treatment

Headlines from the Proactive UK newsroom.

Scancell (LON:SCLP) has received IND approval from the US FDA for its SCIB1 skin cancer treatment. the company will now start a US Phase 2 trial in combination with leading drug Keytruda to see if it reduces toxicity compared to other pairings.

Eco Atlantic (LON:ECO) has reported a 29% increase in the estimate for the amount of oil contained at its Orinduik Block, offshore Guyana. Gross prospective resources are now estimated at 5.14billion barrels on a best basis of which 771mln is net to Eco.

ADM Energy (LON:ADME) has signed a non-binding MOU with leading oil trading group Trafigura to look for opportunities in the African oil sector. ADM will act as the sponsor for opportunities to be presented to Trafigura either as a partner or where it can provide finance.

Chinese markets tumbled as they opened after the Lunar New Year holiday on fears of the impart of coronavirus. The Shanghai Composite index fell nearly 9% before rallying however healthcare shares soared.

Tobacco group Imperial Brands has appointed Stefan Bomhard as its new chief executive. Bomhard joins from Inchcape where he has been CEO for five years.

Digital magazine publisher Future continues to power ahead. Strong organic revenue growth and higher margins means results this year will be materially ahead of current market expectations.

Price: 14.875

Market Cap: £109.87 m

1 Year Share Price Graph



October 2019 May 2020 October 2020

Share Information

Code: SCLP

Listing: LSE

52 week	High	Low
	20.712	4.15682

Sector: Pharma & Biotech

Website: www.scancell.co.uk

Company Synopsis:

Scancell's primary focus is to develop innovative immunotherapies for cancer that stimulate the body's own immune system. A key challenge in the fight against cancer is that many tumours successfully evade the body's own natural defences. Scancell's mission is to overcome this by developing products that stimulate the immune system to treat or prevent cancer.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a

security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).